180 Life Sciences Corp. has announced the completion of a reverse stock split of its common stock, which was effective on February 28, 2024. The reverse stock split was executed at a ratio of 1-for-19, consolidating every nineteen shares of issued and outstanding common stock into one share. This action was taken to comply with the NASDAQ's minimum bid price requirement for continued listing on the NASDAQ Capital Market. The company's common stock began trading on a post-split basis on February 28, 2024, under the unchanged trading symbols 'ATNF' for common stock and 'ATNFW' for public warrants. The total number of outstanding shares was reduced from approximately 11.3 million to about 0.6 million. The reverse stock split was approved by stockholders on February 16, 2024, and...Show More

180 Life Sciences Corp. has announced the completion of a reverse stock split of its common stock, which was effective on February 28, 2024. The reverse stock split was executed at a ratio of 1-for-19, consolidating every nineteen shares of issued and outstanding common stock into one share. This action was taken to comply with the NASDAQ's minimum bid price requirement for continued listing on the NASDAQ Capital Market. The company's common stock began trading on a post-split basis on February 28, 2024, under the unchanged trading symbols 'ATNF' for common stock and 'ATNFW' for public warrants. The total number of outstanding shares was reduced from approximately 11.3 million to about 0.6 million. The reverse stock split was approved by stockholders on February 16, 2024, and the Board of Directors determined the ratio following the Special Meeting. No fractional shares were issued; instead, stockholders received rounded up whole shares. The reverse stock split did not affect the par value or the voting rights of the common stock. The company's transfer agent, Continental Stock Transfer & Trust Company, is providing instructions to stockholders regarding the reverse stock split. The move aims to increase the closing bid price of the company's common stock to satisfy NASDAQ's minimum bid price requirement, following a deficiency notice received from NASDAQ on September 7, 2023.